Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2019 | Preventing progression to multiple myeloma

Here, Shaji Kumar, MD, of the Mayo Clinic, Rochester, MN, discusses the potential benefits of early intervention and treatment to prevent the progression of smoldering myeloma to multiple myeloma. Dr Kumar mentions the Spanish trial which showed improved PFS with lenalidomide and dexamethasone, and the more recent ECOG trial which demonstrated improved PFS with lenalidomide alone. To further benefit patients, new scoring systems need to be developed to accurately identify high risk patients. This interview was recorded at the Controversies in Multiple Myeloma (COMy) 2019 meeting held in Paris, France.